A French pharmaceutical firm reports that a panel of experts has recommended use of its dengue vaccine to the World Health Organization.
The firm is Sanofi Pasteur, which has been one of several firms trying to make a safe dengue vaccine.
The firm said that the Strategic Advisory Group of Experts on Immunization has issued its recommendations on the use of Dengvaxia® dengue vaccine.
The expert panel advised that countries with high dengue transmission consider introduction of the dengue vaccine as part of an integrated disease prevention strategy including vector control to effectively lower their dengue cases, said the firm.
Successful introduction of dengue immunization alongside other prevention efforts should help vulnerable countries to achieve the World Health objectives to reduce dengue morbidity by 25 percent and mortality by 50 percent by 2020, said the firm.
The vaccine’s anticipated impact on dengue fever disease burden is expected to stem from its proven ability to prevent eight out of 10 dengue hospitalizations and up to 93 percent of severe dengue cases, including dengue hemorrhagic fever, in study participants 9 years and older, as demonstrated during 25 months of follow-up studies, said the company.
The recommendations from the expert panel are based on the technical review of clinical data from 25 clinical studies conducted in 15 different endemic and non-endemic countries around the world, including more than 40,000 study participants, said the French firm.
As of March 2016, the vaccine was licensed in Mexico, The Philippines, Brazil and El Salvador, said the firm
Sanofi Pasteur’s vaccine is the culmination of over two decades of scientific innovation and collaboration, as well as 25 clinical studies in 15 countries around the world. Over 40,000 volunteers participated in the Sanofi Pasteur dengue vaccine development program, it added.